UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000003645
Receipt No. R000004410
Scientific Title Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations
Date of disclosure of the study information 2011/01/01
Last modified on 2020/05/27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations

Acronym ALPS trial
Scientific Title Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations

Scientific Title:Acronym ALPS trial
Region
Japan

Condition
Condition advanced non-small-cell lung cancer without harboring sensitive EGFR mutations

Classification by specialty
Medicine in general Pneumology Chest surgery
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 efficacy and safety
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase II

Assessment
Primary outcomes progression free survival
Key secondary outcomes response rate, safety, overall survival, one-year-survial

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Single blind -participants are blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 chemotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria Patients were eligible if they had histologically or cytologically proven unresectable locally advanced NSCLC (clinical stage 3 b with pleral effusion or stage 4, without a history of prior chemotherapy and radiotherapy. In addition, EGFR mutations were analyzed using the available tissue for diagnosis and patients without carrying EGFR mutations were enrolled in the study. Other criteria included the following: 1)age over20 and lessthan 75 years, 2) World Health Organization (WHO) performance status 0-2, 3) measurable disease and an estimated life expectancy over 3 months, 4) adequate bone marrow function (neutrophil count >2000/ul, hemoglobin 9 g/dl, platelets counts > 100,000/ul ), normal hepatic function (total bilirubin level < 1.5 times and AST < 2.5 times the upper normal limits), and renal function (creatinine <1.2 mg/dl, creatinine clearance > 45 ml/min), and partial oxygen tension over 60 torr.
Key exclusion criteria 1) pulmonary fibrosis on chest radiograph, 2)active infection, 3) severe heart disease, 4) past history of hypersensitivity to drugs, 5) pleural or pericardial effusion that required drainage, 6) brain metastasis or 7) pregnancy. Patients with a concomitant active malignancy were also excluded. Other concomitant anticancer therapy or experimental drug administration of any type was not permitted.
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Tomonobu Koizumi
Organization Shinshu University School of Medicine
Division name First Department of Internal Medicine
Zip code
Address 3-1-1 Asahi Matsumoto
TEL 0263-37-2631
Email

Public contact
Name of contact person
1st name
Middle name
Last name Tomonobu Koizumi
Organization Shinshu University School of Medicine
Division name First Department of Internal Medicine
Zip code
Address 3-1-1 Asahi Matsumoto
TEL 0263-37-2631
Homepage URL
Email

Sponsor
Institute Department of Comprehensive Cancer Therapy, Shinshu Universituy School of Medicine
Institute
Department

Funding Source
Organization public insurance
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 信州大学付属病院(長野県)

Other administrative information
Date of disclosure of the study information
2011 Year 01 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2009 Year 12 Month 01 Day
Date of IRB
2009 Year 12 Month 08 Day
Anticipated trial start date
2010 Year 04 Month 01 Day
Last follow-up date
2013 Year 12 Month 01 Day
Date of closure to data entry
2013 Year 12 Month 01 Day
Date trial data considered complete
2013 Year 12 Month 01 Day
Date analysis concluded
2015 Year 12 Month 01 Day

Other
Other related information

Management information
Registered date
2010 Year 05 Month 20 Day
Last modified on
2020 Year 05 Month 27 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004410

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.